Abstract
Early recognition of potential QT/TdP liability is now an essential component of the drug discovery/drug development program. The hERG assay is an indispensable step and a high-quality assay must accompany any investigational new drug (IND) application. While it is the gold standard at present, the hERG assay is too labor-intensive and too low throughput to be used as a screen early in the discovery/development process. A variety of indirect high throughput screens have been used.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Death, Sudden, Cardiac / etiology*
-
Drug Evaluation, Preclinical / methods*
-
Drug Evaluation, Preclinical / standards
-
ERG1 Potassium Channel
-
Ether-A-Go-Go Potassium Channels
-
Humans
-
Long QT Syndrome / etiology
-
Potassium Channels / metabolism*
-
Potassium Channels, Voltage-Gated*
-
Terfenadine / adverse effects
-
Terfenadine / pharmacology
Substances
-
ERG1 Potassium Channel
-
Ether-A-Go-Go Potassium Channels
-
KCNH2 protein, human
-
Potassium Channels
-
Potassium Channels, Voltage-Gated
-
Terfenadine